We could not find the product you're looking for. Please try to search again.
Categories
Couldn't find the answer to your question?
Ximbio is developed by the community, for the community we welcome your suggestions.
suggest an FAQCAN I DEPOSIT OR ACCESS RESEARCH TOOLS THAT CONTAIN CRISPR-Cas9 TECHNOLOGY?
Deposit
If you have developed modified cell lines using CRISPR-Cas9 please get in touch.
Access
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed below. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
ERS Genomics Ltd holds an exclusive worldwide license from Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 for all applications other than use as a human therapeutic. The patent rights belonging to ERS Genomics Ltd are listed below. These patent applications have broad and dominant claims covering CRISPR-Cas9 compositions and methods of genome editing in any organism.
Click here to view ERS Genomics Ltd Granted Patents